The parkinsonism-hyperpyrexia syndrome

Neurocritical Care

Volumn 10, Issue 1, 2009, Pages 136-140

  Newman, Edward J ^a   Grosset, Donald G ^a   Kennedy, Peter G E ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Hyperpyrexia; Parkinsonism; Syndrome

Indexed keywords

AMOXICILLIN; BENSERAZIDE PLUS LEVODOPA; CEFTRIAXONE; CLARITHROMYCIN; CREATINE KINASE; METRONIDAZOLE; RADIOLIGAND; ANTIPARKINSON AGENT;

ADULT; AGITATION; ANTIBIOTIC THERAPY; BRADYKINESIA; BRAIN SCINTISCANNING; CASE REPORT; CHEST INFECTION; COGNITION; CONFUSION; DEHYDRATION; HUMAN; HYPERPYREXIA; LEUKOCYTOSIS; LOBAR PNEUMONIA; MALE; PARKINSON DISEASE; PARKINSONISM; PARKINSONISM HYPERPYREXIA SYNDROME; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SHORT SURVEY; SPEECH DISORDER; THORAX RADIOGRAPHY; TREMOR; VISUAL HALLUCINATION; FATALITY; MALIGNANT HYPERTHERMIA; MIDDLE AGED; PATHOPHYSIOLOGY; REVIEW; SYNDROME; WITHDRAWAL SYNDROME;

ANTIPARKINSON AGENTS; FATAL OUTCOME; HUMANS; MALE; MALIGNANT HYPERTHERMIA; MIDDLE AGED; PARKINSONIAN DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; SYNDROME;

EID: 63249098151     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12028-008-9125-4     Document Type: Short Survey

References (31)

1. J Delay P Pichot T Lemperiere, et al. 1960 A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses Ann Med Psychol (Paris) 118 1 145 52
2. Caroff SN, Mann SC, Campbell EC, et al. Neuroleptic malignant syndrome. In: Frucht SJ, Fahn S, editors. Movement disorder emergencies diagnosis and treatment. New York: Humana Press; 2005. p. 41-52.
3. K Nisijima T Ishiguro 1995 Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome J Psychiatr Res 29 233 44 10.1016/0022-3956(95)00007-R 7473299 10.1016/0022-3956(95)00007-R 1:STN:280:BymD3cfhtVc%3D
4. CM Kipps VS Fung P Grattan-Smith, et al. 2005 Movement disorder emergencies Mov Disord 20 322 34 10.1002/mds.20325 15584031 10.1002/mds.20325 (Pubitemid 40613293)
5. D Berardi M Amore PE Keck Jr, et al. 1998 Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study Biol Psychiatry 44 748 54 10.1016/S0006-3223(97)00530-1 9798079 10.1016/S0006- 3223(97)00530-1 1:STN:280:DyaK1M%2FhsVyisQ%3D%3D (Pubitemid 28496791)
6. PE Keck Jr HG Pope Jr BM Cohen, et al. 1989 Risk factors for neuroleptic malignant syndrome. A case-control study Arch Gen Psychiatry 46 914 8 2572206
7. M Toru O Matsuda K Makiguchi, et al. 1981 Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs J Nerv Ment Dis 169 324 7 10.1097/00005053-198105000-00011 6111584 1:STN:280:Bi6C28bnvVQ%3D
8. H Takubo T Harada T Hashimoto, et al. 2003 A collaborative study on the malignant syndrome in Parkinson's disease and related disorders Parkinsonism Relat Disord 9 Suppl 1 S31 41 10.1016/S1353-8020(02)00122-0 12735913 10.1016/S1353-8020(02)00122-0 (Pubitemid 36539391)
9. M Konagaya Y Goto Y Matsuoka, et al. 1997 Neuroleptic malignant syndrome-like condition in multiple system atrophy J Neurol Neurosurg Psychiatry 63 120 1 9221984 10.1136/jnnp.63.1.120a 1:STN:280:ByiA28rgtlE%3D
10. H Sternbach 1991 The serotonin syndrome Am J Psychiatry 148 705 13 2035713 1:STN:280:By6B2c7jvFc%3D
11. R Mayeux Y Stern K Mulvey, et al. 1985 Reappraisal of temporary levodopa withdrawal ("drug holiday") in Parkinson's disease N Engl J Med 313 724 8 4033697 1:STN:280:BiqB1MnhtFI%3D
12. Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multi-centre European study. Mov Disord. 2008; in press.
13. A Douglas J Morris 2006 It was not just a heatwave! Neuroleptic malignant-like syndrome in a patient with Parkinson's disease Age Ageing 35 640 1 10.1093/ageing/afl096 16943262 10.1093/ageing/afl096 (Pubitemid 44614165)
14. C Gaig MJ Marti E Tolosa, et al. 2005 Parkinsonism-hyperpyrexia syndrome not related to antiparkinsonian treatment withdrawal during the 2003 summer heat wave J Neurol 252 1116 9 10.1007/s00415-005-0798-8 15778809 10.1007/s00415-005-0798-8 1:STN:280:DC%2BD2Mngt1eqsw%3D%3D (Pubitemid 41355844)
15. JB Grace P Thompson 2006 Neuroleptic malignant like syndrome in two patients on cholinesterase inhibitors Int J Geriatr Psychiatry 21 193 4 10.1002/gps.1441 16440373 10.1002/gps.1441 1:STN:280:DC%2BD287gslaktw%3D%3D (Pubitemid 43230864)
16. PH Gordon SJ Frucht 2001 Neuroleptic malignant syndrome in advanced Parkinson's disease Mov Disord 16 960 2 10.1002/mds.1166 11746631 10.1002/mds.1166 1:STN:280:DC%2BD3MnpsFyisQ%3D%3D (Pubitemid 36041203)
17. E Mizuta S Yamasaki M Nakatake, et al. 1993 Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period Neurology 43 1048 9 7605396 1:STN:280:ByyB287lvVI%3D
18. J Shimada R Sakakibara T Uchiyama, et al. 2006 Intestinal pseudo-obstruction and neuroleptic malignant syndrome in a chronically constipated parkinsonian patient Eur J Neurol 13 306 7 10.1111/j.1468-1331.2006. 01151.x 16618352 10.1111/j.1468-1331.2006.01151.x 1:STN:280: DC%2BD283ht1OjtQ%3D%3D
19. SA Factor 2007 Fatal Parkinsonism-hyperpyrexia syndrome in a Parkinson's disease patient while actively treated with deep brain stimulation Mov Disord 22 148 9 10.1002/mds.21172 17080464 10.1002/mds.21172 (Pubitemid 46382692)
20. Factor SA, Santiago A. Parkinsonism-hyperpyrexia syndrome in Parkinson's disease. In: Movement disorder emergencies: Diagnosis and treatment. New York: Humana Press; 2005. p. 29-41.
21. M Ueda M Hamamoto H Nagayama, et al. 1999 Susceptibility to neuroleptic malignant syndrome in Parkinson's disease Neurology 52 777 81 10078727 1:STN:280:DyaK1M7ns1KisQ%3D%3D
22. M Ueda M Hamamoto H Nagayama, et al. 2001 Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome J Neurol Neurosurg Psychiatry 71 111 3 10.1136/jnnp.71.1.111 11413275 10.1136/jnnp.71.1.111 1:STN:280: DC%2BD3MzkvFyquw%3D%3D (Pubitemid 32591951)
23. A Shalev H Hermesh H Munitz 1989 Mortality from neuroleptic malignant syndrome J Clin Psychiatry 50 18 25 2562951 1:STN:280:BiaD1Mzgs1E%3D
24. M Serrano-Duenas 2003 Neuroleptic malignant syndrome-like, or-dopaminergic malignant syndrome-due to levodopa therapy withdrawal. Clinical features in 11 patients Parkinsonism Relat Disord 9 175 8 10.1016/S1353-8020(02) 00035-4 12573874 10.1016/S1353-8020(02)00035-4 (Pubitemid 36173568)
25. T Hashimoto T Tokuda N Hanyu, et al. 2003 Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson's disease Parkinsonism Relat Disord 9 Suppl 1 S25 30 10.1016/S1353-8020(02)00119-0 12735912 10.1016/S1353-8020(02)00119-0 (Pubitemid 36539390)
26. S Ikebe T Harada T Hashimoto, et al. 2003 Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome research group Parkinsonism Relat Disord 9 Suppl 1 S47 9 10.1016/S1353-8020(02)00123-2 12735915 10.1016/S1353-8020(02)00123-2 (Pubitemid 36539393)
27. H Rosenberg M Davis D James, et al. 2007 Malignant hyperthermia Orphanet J Rare Dis 2 21 10.1186/1750-1172-2-21 17456235 10.1186/1750-1172-2-21
28. PS Mueller JW Vester J Fermaglich 1983 Neuroleptic malignant syndrome. Successful treatment with bromocriptine J Am Med Assoc 249 386 8 10.1001/jama.249.3.386 10.1001/jama.249.3.386 1:STN:280:BiyD1cnhtlU%3D (Pubitemid 13167239)
29. Y Sato T Asoh N Metoki, et al. 2003 Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease J Neurol Neurosurg Psychiatry 74 574 6 10.1136/jnnp.74.5.574 12700295 10.1136/jnnp.74.5.574 1:STN:280:DC%2BD3s3gvF2nsg%3D%3D (Pubitemid 36528898)
30. KN Magdalinou A Martin B Kessel 2007 Prescribing medications in Parkinson's disease (PD) patients during acute admissions to a District General Hospital Parkinsonism Relat Disord 13 539 40 10.1016/j.parkreldis.2006.11.006 17241810 10.1016/j.parkreldis.2006.11.006 (Pubitemid 350102299)
31. K Grosset F Needleman G MacPhee, et al. 2004 Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table Mov Disord 19 1370 4 10.1002/mds.20210 15389984 10.1002/mds.20210 (Pubitemid 39534561)